This Saturday, August 20, scientists from the Finlay Institute of Vaccines of Cuba remember the anniversary of the granting of the authorization for the emergency use of the national immunogens Soberana 02 and Soberana Plus.

Read Soberana 02 Achieves 91.2 Percent Efficiency in Her Three-Dose Scheme (+Video)

https://www.lahabana.gob.cu/post_details/es/11372/logra-soberana-02-un-912-por-ciento-de-eficacia-en-su-esquema-de-tres-dosis-video

Both injectables contributed to the control of the pandemic in the Caribbean country, where daily cases decreased and during the last 13 consecutive weeks no patient died as a result of the disease.

"We proudly remember that on August 20, the Center for the State Control of Medicines, Equipment and Medical Devices granted the Authorization for the Emergency Use of Cuban Vaccines Soberana02 and SoberanaPlus," highlights a message from the center on the social network Twitter.

"Today millions of children and adults carry this achievement of Cuban Science in their arms", highlight the researchers of the institution.

The Center for the State Control of Medicines, Equipment and Medical Devices on August 20, 2021 decided to grant the Emergency Use Authorization (AUE) to the Cuban vaccines Soberana 02 and Soberana Plus.

This step was endorsed by compliance with the requirements and parameters demanded in terms of quality, safety and efficacy.

The approval was based on the results obtained in the clinical trials carried out Phases I, II and III, as well as in the intervention study in risk groups and populations and the health intervention, which provided sufficient elements on the safety and efficacy of these vaccines. , which allowed massive use in the Antillean country.

As a result of the talent and dedication of Cuban experts, the Sovereigns responded to the need for Cuba to have its own vaccines to face the COVID-19 pandemic, in a context where the world's large pharmaceutical companies conditioned money, accessibility those essential drugs.

With proven effectiveness, the Sovereigns are part of the Cuban vaccination scheme against the coronavirus and have allowed that, at the end of August 16, 40,464,430 doses have been administered between said vaccines and Abdala, and that 90.1% of our population already has its complete scheme.

Related information

Mambisa vaccine candidate included in the global list of nasal immunogens

https://lahabana.gob.cu/post_details/es/11432/candidato-vacunal-mambisa-included-in-list-global-of-inmunogens-by-nasal-pathway

They report that Abdala Vaccine reaches 100% efficacy against severe disease and death in its phase III trial

https://ahabana.gob.cu/post_details/es/11435/informan-que-vacuna-abdala-alcanza-100-de-efficacia-ante-la-enfermedad-severa-y-la-muerte-en-su- trial-phase-iii#

Read also Abdala shows 92.28% efficacy in his single three-dose scheme

This group of vaccines also works as a booster, a strategy that is applied in the country, to sustain the body's immune response to new variants of the virus